Medy-Tox Inc.
Financials
Valuation Metrics
Medy-Tox Inc.'s Market Cap is ₩4868B. At end of 2025 it was ₩8817B. Ranked #477 of 2,421 in KR market (top 20%), #174 of 1,640 on KOSDAQ (top 11%), #52 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 23%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 486.81B KRW | KR#477/2,421 Sec#52/231 |
| Revenue | 251.08B KRW | KR#915/2,421 Sec#50/231 |
| Net Income | 15.15B KRW | KR#815/2,421 Sec#54/231 |
| Total Assets | 571.87B KRW | KR#712/2,421 Sec#41/231 |
| Net Assets | 379.35B KRW | KR#615/2,421 Sec#39/231 |
| Employees | 776 | KR#326/2,421 Sec#28/231 |
| Value | ||
| P/E | 32.14x | KR#1,326/2,421 Sec#82/231 |
| P/B | 1.28x | KR#1,676/2,421 Sec#114/231 |
| PEG | 0.15x | KR#497/2,421 Sec#29/231 |
| P/S | 1.94x | KR#1,793/2,421 Sec#103/231 |
| EV/EBITDA | 37.36x | KR#1,269/2,421 Sec#80/231 |
| FCF Yield | 9.40% | KR#631/2,421 Sec#29/231 |
| Profitability | ||
| ROE | 3.99% | KR#1,218/2,421 Sec#85/231 |
| ROA | 2.65% | KR#1,097/2,421 Sec#81/231 |
| Op. Margin | 6.91% | KR#737/2,421 Sec#58/231 |
| Revenue Growth | 7.01% | KR#1,072/2,421 Sec#103/231 |
| Earnings Growth | 216.81% | KR#231/2,421 Sec#14/231 |
| Financial Health | ||
| Debt Ratio | 50.75% | KR#968/2,421 Sec#111/231 |
| Total Debt | 208.24B KRW | KR#504/2,421 Sec#26/231 |
| FCF | 45.75B KRW | KR#323/2,421 Sec#18/231 |
| Cash | 46.93B KRW | KR#771/2,421 Sec#47/231 |
| Current Ratio | 1.03x | KR#1,684/2,421 Sec#169/231 |
| Net Debt/EBITDA | 9.30x | KR#1,196/2,421 Sec#87/231 |
| Dividend | ||
| Div. Yield | 1.78% | KR#926/2,421 Sec#48/231 |
| Div. Growth | 9.09% | KR#619/2,421 Sec#34/231 |
| Performance | ||
| 1Y Return | -45.55% | KR#1,950/2,421 Sec#167/231 |
| 1M Return | -2.49% | KR#1,522/2,421 Sec#121/231 |
| From 52W High | -52.73% | KR#1,522/2,421 Sec#117/231 |
| 1Y MDD | -51.88% | KR#1,064/2,421 Sec#87/231 |
| Trading | ||
| Volume | 23,708 shares | KR#1,500/2,421 Sec#147/231 |
| Trading Value | 1.58B KRW | KR#606/2,421 Sec#59/231 |
| Foreign Own. | 14.32% | KR#335/2,421 Sec#22/231 |
| Per Share | ||
| EPS | 2,076 KRW | KR#440/2,421 Sec#28/231 |
| BPS | 51,976 KRW | KR#259/2,421 Sec#16/231 |
Company Info
Established in 2000 and listed on KOSDAQ in 2009, Meditox engages in the research, development, manufacturing, and sale of Botulinum Toxin Type A and biopharmaceuticals. The company's main products are Meditoxin Inj., Coretox, and Innotox, developed with proprietary original technology. With the KFDA product approval for Neurtoxin in 2023, it is expanding into domestic and international markets while diversifying its portfolio with hyaluronic acid fillers, liquid toxin formulations for US entry, and genetically recombinant toxins. Meditox is headquartered in Cheongwon-gun, Chungcheongbuk-do.